Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
 |
Anesiva Announces Second Quarter 2008 Financial Results and Update
Aug 7, 2008
|
17.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the second quarter and six months ended June 30, 2008.
"The 2008 second quarter marked a significant advance for Anesiva as we introduced Zingo(TM) in the U.S. pediatri...
|
|
 |
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Jul 17, 2008
|
11.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has begun a Phase 2 clinical trial of Adlea(TM), the company's long-acting, site specific, non-opioid drug candidate for the management of acute pain in patients undergoing arthroscopic shoulder surgery i...
|
|
 |
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Jun 30, 2008
|
15.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has launched its first commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. Zingo is an easy-to-administer, single-use, needle-free system that reduces ...
|
|
 |
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Jun 16, 2008
|
11.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the appointment of Michael L. Kranda as president, chief executive officer and a member of the company's board of directors, effective June 16, 2008. Mr. Kranda succeeds John P. McLaughlin, who resigned as chief ...
|
|
 |
Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Jun 5, 2008
|
11.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics, Inc. (TFT). NF-kB Transcrip...
|
|
|